Critical care drug update. Part I.
Chase
S L
SL
D000077284:Abciximab; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use*; D003422:Critical Care; D004347:Drug Interactions; D016903:Drug Monitoring; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009730:Nursing Assessment; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D000911:Antibodies, Monoclonal; D006490:Hemostatics; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D007611:Aprotinin; D000638:Amiodarone; D000077284:Abciximab